Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cuts

Angus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discussed a potential deal that would form a $400 billion entity, but no concrete terms have been disclosed.

The piece argues that combining the two pipelines would raise serious antitrust scrutiny and could stall ongoing drug development programs. Regulatory reviewers are likely to examine the overlap in therapeutic areas and the market power the new company would wield.

Liu also points out that a merger of this scale would likely result in significant job reductions as duplicate functions are eliminated. He suggests that the broader biopharma ecosystem could suffer as smaller innovators lose a partner and patients may face delayed access to new treatments.

Overall, the editorial frames the proposed combination as a risky move that could damage both companies and the industry at large.